Despite a recent positive economic modeling study, the debate over appropriate use of the ME panel seems likely to continue until more outcomes studies are conducted.
Worcester Polytechnic Institute researchers are developing an inexpensive handheld platform that could provide C. difficile test results in minutes.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The research highlighted particular challenges for gram-negative organisms among a population of higher-risk patients.
Excluding IPOs, the funding environment for private venture-backed financing Dx deals in the US and Europe was remarkably similar in 2018 to 2017, according to Silicon Valley Bank.
The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.
The company plans to launch on the platform tests for diagnosing sexually transmitted diseases and for distinguishing between viral and bacterial infections.
The newly launched RT-PCR-based molecular diagnostic kits are designed for use in monitoring post-transplantation and immunosuppressed patients.
The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.
The enteric panel detects the viral cause of infectious diarrhea symptoms including norovirus, rotavirus, adenovirus, human astrovirus, and sapovirus.
The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.
In a study, the diagnostic and delivery capsules remained in the GI tract of pigs for more than a month and transmitted wireless temperature signals.
The firm has added two new targets to make the Sofia 2 POC Lyme+ Fluorescent Immunoassay more relevant to Lyme disease pathogens in Europe.
The bottles support growth of aerobic and anaerobic organisms for quality control testing of platelets.
The company developed the test with Boston University researchers as part of an effort to push its surface-enhanced Raman scattering tech for POC applications.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
The firms will jointly invest in establishing a joint venture company in China, and Autobio has also invested €10 million in Mobidiag.
The firm’s test for detecting flu and differentiating between subtypes A and B is being launched in Europe, Asia, and South America.
The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
The test is a lateral flow, in vitro qualitative immunoassay that detects human antibodies to HIV virus type 1 and type 2 in whole blood.